# Safety and Efficacy of Concurrent Administration of Influenza Vaccine in Patients Undergoing Anti-PD-1 Immunotherapy (Nivolumab, Pembrolizumab)

> **NCT03061955** · — · COMPLETED · sponsor: **Wake Forest University Health Sciences** · enrollment: 28 (actual)

## Conditions studied

- Influenza Virus Vaccine Adverse Reaction (Disorder)
- Influenza
- Malignancy

## Interventions

- **BIOLOGICAL:** influenza vaccination

## Key facts

- **NCT ID:** NCT03061955
- **Lead sponsor:** Wake Forest University Health Sciences
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10-01
- **Primary completion:** 2017-03-31
- **Final completion:** 2019-04-26
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2024-10-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03061955

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03061955, "Safety and Efficacy of Concurrent Administration of Influenza Vaccine in Patients Undergoing Anti-PD-1 Immunotherapy (Nivolumab, Pembrolizumab)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03061955. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*